6 October 2021 - - Australia-based molecular diagnostic solutions developer SpeeDx Pty. Ltd has expanded its product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest, the company said.

The PlexPrime SARS-CoV-2 Genotyping product line has rapidly expanded since launching in July, utilising the company's unique universal substrate approach and patented multiplexing technology.

The suite of products can be used independently or combined to support laboratory investigation and monitoring efforts of key SARS-CoV-2 variants of interest or concern.

PlexPrime SARS-CoV-2 L452Q Lambda is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda), in addition to an RdRp gene target of SARS-CoV-2.

This reagent is the third product in the PlexPrime SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrimeP681R Delta reagents.

Compatible with standard qPCR and liquid handling instrumentation, the PlexPrime SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.

SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction technology has driven multiplex detection and priming strategies.

Product portfolios focus on multiplex diagnostics for sexually transmitted infection, antibiotic resistance markers, and respiratory disease.